Related Experiment Video
Updated: Jul 17, 2025
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
3.4K
Cutaneous T-cell Lymphoma Progression: A Potential Dupilumab Pitfall.
Hamza Malick1, Allessia Wilson2, Marshall Hall2
1Medicine, Texas Agricultural and Mechanical College of Medicine, Dallas, USA.
Cureus
|September 5, 2023
Summary
Dupilumab, a biologic therapy for inflammatory conditions, may paradoxically worsen or accelerate cutaneous T-cell lymphoma (CTCL) in some patients. This case highlights the need for vigilance and further research into this potential association.
Area of Science:
- Immunology
- Dermatology
- Oncology
Background:
- Dupilumab is a monoclonal antibody targeting key inflammatory pathways, widely used for atopic dermatitis and other inflammatory diseases.
- Recent literature suggests a potential link between dupilumab use and the exacerbation or accelerated progression of cutaneous T-cell lymphoma (CTCL).
Observation:
- A 60-year-old African American female developed CTCL three months after initiating dupilumab for presumed atopic dermatitis.
- The patient's presentation and disease course warrant careful consideration of potential drug-induced effects.
Findings:
- This case report documents a potential association between dupilumab therapy and the development of CTCL.
- Morphological differences in patient presentation may aid in early diagnosis.
Implications:
- Physicians should be aware of the potential for dupilumab to unmask or accelerate CTCL.
- Further investigation is crucial to elucidate the precise relationship between dupilumab and CTCL development and progression.
